CClinicalTrials.gg
CompletedNCT00520312Updated Apr 9, 2014

Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease

An observational study in Peripheral Vascular Diseases, sponsored by Northwestern University. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-09.

Sponsored by Northwestern University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
519
Ages
21 Years and older
Sex
All
01

Study summary

Peripheral arterial disease (PAD) is a disease in which fatty build-up, or "plaque," accumulates in the peripheral arteries. People with PAD often experience leg pain while walking due to reduced blood flow to the legs. This study will use magnetic resonance imaging (MRI) techniques to examine how specific features of plaque build-up in the leg arteries affect walking ability, leg strength, and balance in people with PAD.

Read the detailed description

Plaque build-up caused by atherosclerosis increases the risk of blood clots, heart attack, and stroke. Blockages of plaque can occur in different areas of the body. PAD, a circulatory disorder in which blockages occur in the peripheral arteries, is one manifestation of atherosclerosis. Individuals with PAD experience reduced blood flow to the legs, which may cause leg pain while walking. This study will use MRI techniques to examine how characteristics of plaque build-up in the leg arteries change over time and how this change affects function, walking ability, leg strength, and balance in people with PAD. Results from this study may be used to shape future research studies that will attempt to identify more effective treatments for people with PAD.

This study will enroll people with PAD, as well as a smaller control group of people who do not have PAD. At an initial study visit, study researchers will interview participants to collect information about their medical history, daily activity level, walking ability, and mental functioning. Blood collection and a leg MRI will occur. Also, blood flow to the legs will be measured by comparing blood pressure measurements in the arms and legs. Leg function will be measured through a series of timed walks, leg strength exercises, and muscle power exercises. Questionnaires to assess participants' medical history will be completed by each participant's primary care doctor, and study researchers will review participants' medical records. Participants with knee pain will have a knee x-ray, and participants may wear a small device called an accelerometer for 1 week to monitor physical activity levels. During the second and third study visits, occurring at one and two year follow-up, blood flow, leg function, and leg strength will be measured. If participants cannot attend either study visit, researchers may visit participants at their home or conduct an interview over the phone. Study researchers may contact participants by phone once or twice a year for follow-up.

02

Conditions studied

  • Peripheral Vascular Diseases

Keywords

  • Peripheral Arterial Disease
  • PAD
  • Functional Impairment
  • Magnetic Resonance Imaging
03

In context

Peripheral Arterial Disease

1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.

This study's enrollment of 519 is above the median of 190 across 410 observational studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,395 studies on the registry; 198 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Ankle Brachial Index less than 1 in participants

Inclusion criteria

  • For participants with PAD: lowest leg ankle-brachial index (ABI) less than or equal to 0.999
  • For participants in the control group: lowest ABI between 1.00 to 1.30

Exclusion criteria

Exclusion Criteria:

  • Foot amputation, leg amputation, or gangrene
  • Recent liver transplantation
  • Requires oxygen on ambulation
  • End stage renal disease
  • Confined to a wheelchair
  • Lives in a nursing home
  • Low life expectancy
  • Mini-Mental Status Exam (MMSE) score of less than 23 out of 30
  • Communication difficulty due to language barriers
  • Inability to tolerate MRI testing for any reason
  • Six-minute walk performance limited primarily by pulmonary disease, legal blindness, or severe lower extremity arthritis
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
519 participants (actual)
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Functional Performance: 6-minute walk performance

    Time frame: Baseline, 12 months, 24 months

  2. MRI: Mean Plaque Volume

    Time frame: Baseline, 24 months

Secondary outcomes

  1. Four meter walking velocity (usual pace), four meter walking velocity (fastest pace), SPPB

    Time frame: Baseline, 12 months, 24 months

  2. MRI: maximum plaque volume, external remodeling, mean percent lumen reduction, maximum percent lumen reduction

    Time frame: Baseline, 24 months

07

Study locations

1 site
  • Northwestern University
    Chicago, Illinois 60611, United States
08

References and documents

Publications

  • Polonsky TS, Liu K, Tian L, Carr J, Carroll TJ, Berry J, Criqui MH, Ferrucci L, Guralnik JM, Kibbe MR, Kramer CM, Li F, Xu D, Zhao X, Yuan C, McDermott MM. High-risk plaque in the superficial femoral artery of people with peripheral artery disease: prevalence and associated clinical characteristics. Atherosclerosis. 2014 Nov;237(1):169-76. doi: 10.1016/j.atherosclerosis.2014.08.034. Epub 2014 Sep 2. PubMed 25240112 ↗
  • McDermott MM, Carroll TJ, Kibbe M, Kramer CM, Liu K, Guralnik JM, Keeling AN, Criqui MH, Ferrucci L, Yuan C, Tian L, Liao Y, Berry J, Zhao L, Carr J. Proximal superficial femoral artery occlusion, collateral vessels, and walking performance in peripheral artery disease. JACC Cardiovasc Imaging. 2013 Jun;6(6):687-94. doi: 10.1016/j.jcmg.2012.10.024. Epub 2013 May 4. PubMed 23647796 ↗
  • McDermott MM, Liu K, Carr J, Criqui MH, Tian L, Li D, Ferrucci L, Guralnik JM, Kramer CM, Yuan C, Kibbe M, Pearce WH, Berry J, McCarthy W, Liao Y, Xu D, Orozco J, Carroll TJ. Superficial femoral artery plaque, the ankle-brachial index, and leg symptoms in peripheral arterial disease: the walking and leg circulation study (WALCS) III. Circ Cardiovasc Imaging. 2011 May;4(3):246-52. doi: 10.1161/CIRCIMAGING.110.962183. Epub 2011 Mar 24. PubMed 21436300 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00520312
Lead sponsor
Northwestern University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Mary McDermott (Principal Investigator, Northwestern University) — Principal investigator
First posted
Aug 24, 2007
Start date
Oct 2007
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Apr 9, 2014

Study contacts

Mary M. McDermott, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion